Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 372,384 shares, a growth of 281.1% from the December 31st total of 97,715 shares. Based on an average daily volume of 2,377 shares, the days-to-cover ratio is presently 156.7 days. Based on an average daily volume of 2,377 shares, the days-to-cover ratio is presently 156.7 days.

Innovent Biologics Stock Performance

Shares of OTCMKTS IVBXF traded up $0.43 during midday trading on Thursday, hitting $10.40. 2,485 shares of the company’s stock were exchanged, compared to its average volume of 1,577. Innovent Biologics has a twelve month low of $4.25 and a twelve month high of $15.12. The stock’s 50 day moving average price is $10.98 and its 200-day moving average price is $11.64.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).